Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Drugs. 2022 Nov;82(16):1603-1609. doi: 10.1007/s40265-022-01795-z.
Darinaparsin (Darvias), an organoarsenic drug, is a novel mitochondrial-targeted anticancer agent currently being developed by Solasia Pharma K.K for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). An intravenous formulation of darinaparsin has been approved for the treatment of relapsed or refractory PTCL in Japan, and preparation for the next stage of the clinical development program for this indication is currently underway in China, the USA and the EU. This article summarizes the milestones in the development of darinaparsin leading to this first approval for relapsed or refractory PTCL.
达尼泊司他（达维巴嗪），一种有机砷药物，是一种新型的靶向线粒体的抗癌药物，目前由 Solasia Pharma K.K 公司开发，用于治疗复发或难治性外周 T 细胞淋巴瘤（PTCL）。达尼泊司他的静脉制剂已在日本获批用于治疗复发或难治性 PTCL，目前正在中国、美国和欧盟为该适应症的下一阶段临床开发计划做准备。本文总结了达尼泊司他开发过程中的重要里程碑，这些里程碑促成了该药在复发或难治性 PTCL 中的首次获批。
